University of Ioannina
Πεπτιδικά ανάλογα της αιμοπεταλιακής ιντεγκρίνης αΙΙbβ3: δράση τους ως αλλοστερικών αναστολέων της ενεργοποίησής της
Abstract
dc:descriptionPlatelet thrombus formation is an essential, physiological and pathological reaction that depends on platelets’ ability to aggregate. Platelet aggregation is mediated by the platelet integrin αIIbβ3 (GPIIb/IIIa). In resting platelets the integrin αIIbβ3 is in a low-affinity state, unable to interact with soluble fibrinogen. During platelet activation, inside-out signalling induces cytoplasmic tail separation through talin binding to β3 tail and conformational changes of the integrin that dramatically increase its affinity for the ligand. Following fibrinogen binding, integrin αIIbβ3, generates “outside-in” signals which further enhance platelet activation and contribute to thrombus consolidation and stabilization. Integrin affinity increase relies on several major conformational changes, namely integrin extension at the knees, leg separation, and a β3 subunit swing-out motion at the interface between the βI and hybrid domains, converting the headpiece from the ‘closed’ to ‘open’ conformation, thus facilitating ligand binding by the headpiece.It has been proved that the octapeptide YMESRADR derived from the β-propeler domain of integrin αIIb is an active inhibitor of platelet aggregation. It was also shown crystallography modelling analysis, that it is able to act as a substitute for the β-ribbon by forming a clasp restraining the β3 hybrid and βI domains in a closed conformation through the salt bridges: D319(αΙΙb)-K384(β3) and R320(αΙΙb)-E356(β3). The purpose of this study was to investigate further and explain the mechanism of the inhibitory effect of the YMESRADR octapeptide on integrin αIIbβ3 activation. The inhibitory effect of the peptide and its structural requirements for its inhibitory activity was tested i) in light-transmission aggregometry in human washed platelets ii) in flow cytometry experiments, iii) in CHO cells adhesion under flow conditions and iv) in upon thrombin-induced talin recruitment to platelet integrin αIIbβ3. Our experimental data showed that the octapeptide inhibited thrombin-induced platelet aggregation, fibrinogen and PAC-1 binding to activated platelets, alanine replacement or deletion of the amino acids of the octapeptide underline the importance of D319, R317, R320, as well as Y313 for the inhibitory activity of the peptide. YMESRADR at 500 μΜ also strongly impaired adhesion onto fibrinogen under flow of CHO cells expressing either the wild type receptor or the receptor with mutations in the αIIb β-ribbon. Additionally, the octapeptide at the above concentration was unable to inhibit adhesion of CHO cells expressing the β3K384/A mutant, demonstrating the important role played by the salt bridge between D319-K384 (β3) in the octapeptide's inhibitory activity. Finally, after western blotting experiments it was shown that the octapeptide did not affect the association of talin with the integrin β3 cytoplasmic tail, which occurres during platelet activation induced by thrombin. Οur data and those of the literature highlight the important role of the IIb -ribbon in maintaining the closed inactive conformation of IIb3 by securing the hinge angle between the βI and the hybrid domain. This precludes conformational changes necessary for the extension of integrin αIIbβ3 to its high-affinity ligand-binding state.It was previously shown by our experiments, that a lipid-modified platelet permeable peptide, which corresponds to the intracellular acidic membrane distal sequence 1000LEEDDEEGE1008 of αIIb, pal-1000-1008, potently inhibits thrombin induced human platelet aggregation and after alanine-scanning test of this amino-acid sequence we concluded that, the total charge, size and peptide’s complete primary structure play an important role in the expression of the biological activity and none of the residues seems to support the entire activity. After flow cytometry experiments, we showed that pal-1000-1008 peptide at 100 μΜ significantly inhibited PAC-1 and fibrinogen binding to ADP-activated platelets. The investigation of the mechanism of the above binding inhibition through the inhibitory activity of the peptide on talin binding to the αIIbβ3, necessary and sufficient step of the inside-out signaling of the integrin was followed. Talin binding breaks the clasp between the α and β cytoplasmic tails, induces integrin cytoplasmic tail separation, resulting in integrin activation, by inducing significant changes in the integrin structure. Our results showed that, pal-K-1000-1008 modified the association of talin with the integrin β3 cytoplasmic tail, which occurred during platelet activation induced by thrombin. In presence of the peptide, this association becomes transient and begins to disappear from the second min of aggregation and then. Thus, by inhibiting talin-integrin interaction, the peptide seems to rearrange α-β tail associations, and to restore the equilibrium of the inactive state of the integrin, leading to platelet aggregation inhibition. It has been suggested that modulation of integrin–talin interactions may provide an attractive target for antithrombotics. The intracellular peptide approach of the present study could be promising for the development of future anti-thrombotic drugs.Our final aim of the present thesis was the investigation of the existence of a synergistic inhibitory effect of the intra- and extracellular peptide on platelet activation and aggregation, on integrin inside-out signalling as well as on the phosphorylation of signalling proteins FAK and ERK. The peptides, at threshold inhibitory concentrations, added consecutively, were able to provoke almost full inhibition of platelet aggregation. The incubation, firstly with pal-Κ-1000-1008 at 50 μΜ followed by YMESRADR at 75 μΜ, showed also a synergistic inhibitory activity on platelet activation. Their synergistic inhibitory effect on fibrinogen and on PAC-1 binding to activated platelets shows their ability to inhibit, when added consequently, the activation of the integrin. Furthermore, we wanted to investigate the mechanism of the above binding inhibition through the inhibitory activity of the peptides on talin binding to the αIIbβ3. Interestingly, we found that the synergistic effect of the peptides inhibited the association of talin with β3 integrin at the fourth min of activation by thrombin. FAK phosphorylation is a post-aggregation event. ERK activation is independent from platelet aggregation and its phosphorylation and activity are enhanced by fibrinogen competitive RGD-peptide inhibitors. The combination of peptides, at the above concentrations, inhibited FAK phosphorylation as well as ERK2 phosphorylation.In conclusion, this study shows for the first time, that an allosteric inhibition of αΙΙbβ3, induced by the use of the intracellular in combination with the extracellular peptide inhibitor, at threshold inhibitory concentrations, may provide an alternative pharmacological approach to the current αIIbβ3 RGD-like antagonists and provide new potential therapeutic approach to thrombus formation and pathological diseases
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gkourogianni, Alexia
- Γκουρογιάννη, Αλεξία
Subjects
dc:subject × 24- Αιμοπετάλια
- Ιντεγκρίνη αΙΙbβ3
- Αιμοπεταλιακή συσσώρευση
- Θρόμβωση
- εξωκυττάριος αναστολέας της συσσώρευσης
- Αλλοστερικος αναστολέας
- Παλμιτοϋλιομένος αΙΙb ενδοκυττάριος αναστολέας της συσσώρευσης
- Συνεργατική δράση
- Κυτταροσκελετική πρωτεΐνη ταλίνη
- Platelets
- Integrin αΙΙbβ3
- Platelet aggregation
- Thrombosis
- extracellular inhibitor of platelet aggregation
- allosteric inhibitor
- αΙΙb intracellular inhibitor of aggregation
- synergistic effect
- Cytoskeletal protein talin
- Φυσικές Επιστήμες
- Χημεία
- Βιολογία
- Natural Sciences
- Chemical Sciences
- Biological Sciences
Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35133